Sandbox endocarditis: Difference between revisions
(6 intermediate revisions by the same user not shown) | |||
Line 104: | Line 104: | ||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Vancomycin|Vancomycin hydrochloride]] 40 mg/kg per 24 h IV in 2–3 equally divided doses''''' | |style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Vancomycin|Vancomycin hydrochloride]] 40 mg/kg per 24 h IV in 2–3 equally divided doses''''' | ||
|- | |- | ||
|Minimum inhibitory concentration ≤ 0.12 μg/mL. | | | ||
Minimum inhibitory concentration ≤ 0.12 μg/mL. | |||
:† Preferred in most patients >65 y or patients with impairment of 8th cranial nerve function or renal function. | :† Preferred in most patients >65 y or patients with impairment of 8th cranial nerve function or renal function. | ||
Line 121: | Line 122: | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Native Valve Endocarditis Caused by Strains of Viridans Group Streptococci and Streptococcus | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Native Valve Endocarditis Caused by Strains of Viridans Group Streptococci and Streptococcus Bovis Relatively Resistant to Penicillin (MIC >0.12 μg/mL- ≤ 0.5 μg/mL))}} | ||
|- | |- | ||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | !style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | ||
Line 189: | Line 190: | ||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''40 mg/kg per 24 h IV or in 2 or 3 equally divided doses''''' | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''40 mg/kg per 24 h IV or in 2 or 3 equally divided doses''''' | ||
|- | |- | ||
|*Dosages recommended are for patients with normal renal function. | | | ||
*Dosages recommended are for patients with normal renal function. | |||
:† Penicillin or ceftriaxone together with gentamicin has not demonstrated superior cure rates compared with monotherapy with penicillin or ceftriaxone for patients with highly susceptible strain; gentamicin therapy should not be administered to patients with creatinine clearance of <30 mL/min. | :† Penicillin or ceftriaxone together with gentamicin has not demonstrated superior cure rates compared with monotherapy with penicillin or ceftriaxone for patients with highly susceptible strain; gentamicin therapy should not be administered to patients with creatinine clearance of <30 mL/min. | ||
Line 202: | Line 204: | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Penicillin | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Penicillin Relatively or Fully Resistant Strain (MIC >0.12 >μg/mL)}} | ||
|- | |- | ||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | !style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | ||
Line 235: | Line 237: | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Relatively Penicillin-Resistant Streptococci (MIC 0.2–0.5 µg/ml}} | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Relatively Penicillin-Resistant Streptococci (MIC 0.2–0.5 µg/ml)}} | ||
|- | |- | ||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | !style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | ||
Line 261: | Line 263: | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Relatively Penicillin-Resistant Streptococci(MIC > 0.5 µg/ml, consider Enterococcal regimen}} | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Relatively Penicillin-Resistant Streptococci(MIC > 0.5 µg/ml, consider Enterococcal regimen)}} | ||
|- | |- | ||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | !style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | ||
Line 340: | Line 342: | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table18" style="background: #FFFFFF;" | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table18" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: | {| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin}} | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin}} | ||
|- | |- | ||
Line 369: | Line 371: | ||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30 mg/kg I.V. daily in divided doses q. 12 hour X 4–6 Wks'''''<br> ''PLUS'' <br> ▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses X 4-6 Wks''''' | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30 mg/kg I.V. daily in divided doses q. 12 hour X 4–6 Wks'''''<br> ''PLUS'' <br> ▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses X 4-6 Wks''''' | ||
|- | |- | ||
|*Native valve: 4-wk therapy recommended for patients with symptoms of illness < 3 months. | | | ||
*Native valve: 4-wk therapy recommended for patients with symptoms of illness < 3 months. | |||
*6-wk therapy recommended for patients with symptoms >3 months. | *6-wk therapy recommended for patients with symptoms >3 months. | ||
*Prosthetic valve or other prosthetic cardiac material: minimum of 6 wk of therapy recommended. | *Prosthetic valve or other prosthetic cardiac material: minimum of 6 wk of therapy recommended. | ||
Line 380: | Line 383: | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table19" style="background: #FFFFFF;" | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table19" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: | {| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin}} | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin}} | ||
|- | |- | ||
Line 423: | Line 426: | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table20" style="background: #FFFFFF;" | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table20" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: | {| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|β-Lactamase–producing strain}} | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|β-Lactamase–producing strain}} | ||
|- | |- | ||
Line 460: | Line 463: | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table21" style="background: #FFFFFF;" | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table21" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: | {| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|E faecium}} | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|E faecium}} | ||
|- | |- |
Latest revision as of 21:12, 5 March 2014
Streptococci
▸ Click on the following categories to expand treatment regimens.
Native Valve Endocarditis Caused by Viridans Group Streptococci and Streptococcus Bovis ▸ Viridans Group Streptococci and Streptococcus Bovis Highly Penicillin-Susceptible ▸ Viridans Group Streptococci and Streptococcus Bovis Relatively Penicillin Resistant (MIC >0.12 μg/mL- ≤ 0.5 μg/mL) Prosthetic Valves Endocarditis Caused by Viridans Group Streptococci and Streptococcus Bovis ▸ Viridans Group Streptococci and Streptococcus Bovis Penicillin-Susceptible Strain (MIC ≤ 0.12 μg/mL) ▸ Viridans Group Streptococci and Streptococcus Bovis Penicillin Relatively or Fully Resistant Strain (MIC >0.12 μg/mL) ▸ Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin-Resistant Streptococci (MIC 0.2–0.5 µg/ml) ▸ Relatively Penicillin-Resistant Streptococci (MIC > 0.5 µg/ml) ▸ Unable to tolerate Penicillin or Ceftriaxone |
|
|
|
|
|
|
|
Enterococci
Endocarditis Caused by Enterococci ▸ Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin ▸ Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin ▸ Enterococci Strains Resistant to Penicillin and Susceptible to Aminoglycoside and Vancomycin ▸ Enterococci Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin |
|
|
|
|
Staphylococci
Native Valve Endocarditis caused by Staphylococci in the Absence of Prosthetic Material ▸ Staphylococci (Methicillin Susceptible) ▸ Staphylococci (Methicillin-resistant) with Penicillin G Anaphylactoid Hypersensitivity Prosthetic Valves Endocarditis or Other Prosthetic Material Caused by Staphylococci ▸ Oxacillin-Susceptible Strains ▸ Oxacillin-Resistant Strains |
|
|
|
|
HACEK Organisms
HACEK organisms are more indolent and the infection is less complicated. [1]
▸ Therapy for Both Native and Prosthetic Valve Endocarditis Caused by HACEK Microorganisms |
|
- ↑ Baddour, LM.; Wilson, WR.; Bayer, AS.; Fowler, VG.; Bolger, AF.; Levison, ME.; Ferrieri, P.; Gerber, MA.; Tani, LY. (2005). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145. Unknown parameter
|month=
ignored (help)